drugset / Trial / NCT00948909

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909

Phase 2 Completed 274 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.

Timeline

Start
2009-10
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-126 Small molecule 5 mg
Subject ABT-126 Small molecule 25 mg
Comparator Donepezil Small molecule 10 mg

Indications